Table 7.
Degree centrality of promising drug candidates on the validation network.
| Rank | Drug name | Degree centrality |
|---|---|---|
| 1 | Tamoxifen∗ | 0.661 |
| 2 | Doxorubicin∗ | 0.554 |
| 3 | Paclitaxel∗ | 0.536 |
| 4 | Fulvestrant∗ | 0.268 |
| 5 | Methotrexate∗ | 0.268 |
| 6 | Camptothecin∗∗ | 0.232 |
| 7 | Letrozole∗ | 0.214 |
| 8 | Vinblastine∗ | 0.196 |
| 9 | Exemestane∗ | 0.179 |
| 10 | Megestrol∗ | 0.125 |
| 11 | Aminoglutethimide∗ | 0.107 |
| 12 | MS-275∗∗ | 0.089 |
| 13 | Alsterpaullone∗∗ | 0.071 |
| 14 | GW-8510∗∗ | 0.036 |
| 15 | Phenoxybenzamine∗∗ | 0.036 |
| 16 | Celastrol∗∗ | 0.036 |
| 17 | Tyrphostin_AG-825∗∗ | 0.018 |
∗Known breast cancer drug. ∗∗Potential drug candidate for repositioning.